[ad_1]
Jakarta, CNBC Indonesia – The pharmaceutical giants Pfizer and BioNTech have just announced good results from the Covid-19 vaccine that they are currently developing. So what is the selling price of this vaccine?
BioNTech plans to price the two-shot coronavirus (Covid-19) vaccine regimen below market prices and will differentiate prices between countries or regions. At a Financial Times online event, BioNTech chief strategist Ryan Richardson said the price of the vaccine, which was developed jointly with Pfizer, would reflect the financial risks that private sector investors face today.
“We have tried to follow a balanced approach that recognizes that innovation requires capital and investment, so we plan to price our vaccines well below normal market prices that reflect our situation and with the aim of ensuring global access. Richardson said. as reported by Reuters.
“I hope there will be different prices in certain regions of the world,” he added, declining to elaborate on what the different price tags mean. “
On Monday (September 11, 2020), the BioNTech and Pfizer vaccines were shown to be 90% effective, based on results of preliminary trials.
Last July, Pfizer collaborated with the United States government to supply 100 million doses of potential vaccine at a price of US $ 39 (Rp. 540 thousand, assuming Rp. 14,047 / US $) per two-dose immunization. , or US $ 19.5 (Rp. 270 thousand) per dose, with the option to sell another 500 million doses provided they are negotiated separately.
BioNTech’s chief strategist emphasized that, although the German group has received support from the public sector, the risks its investors are taking will be to obtain financial returns from vaccines in the future.
“We face significant financial risks. We have increased our capital in the capital market,” he said.
Richard Hatchett, executive director of the Coalition for Epidemic Preparedness Innovation (CEPI), said the Pfizer and BioNTech projects are among the top 10 vaccine developers that have not received “substantial funding from the public sector.”
In June, the European Investment Bank, the financial agency of the European Union, provided BioNTech with € 100 million in debt financing for the development and manufacture of the Covid-19 vaccine.
Meanwhile, the German research ministry gave BioNTech 375 million euros in September, based on certain achievements, also to increase the development and production of its vaccine.
[Gambas:Video CNBC](Roy / Roy)
